We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

90 hedge funds and large institutions have $156M invested in BioSpecifics Technologies Corp. in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 48 increasing their positions, 16 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 16

17% more capital invested

Capital invested by funds: $134M → $156M (+$22.6M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

1% less funds holding

Funds holding: 9190 (-1)

Holders
90
Holders Change
-1
Holders Change %
-1.1%
% of All Funds
2.4%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
9
Increased
48
Reduced
16
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SCA
51
Secor Capital Advisors
New York
$665K +$331K +9,046 +119%
GA
52
Geneva Advisors
Illinois
$562K +$27.7K +755 +6%
California State Teachers Retirement System (CalSTRS)
53
California State Teachers Retirement System (CalSTRS)
California
$452K +$33.8K +922 +9%
New York State Common Retirement Fund
54
New York State Common Retirement Fund
New York
$428K -$40.5K -1,106 -9%
CS
55
Credit Suisse
Switzerland
$411K +$150K +4,090 +66%
SGAM
56
Smith Group Asset Management
Texas
$393K +$346K +9,450 +2,374%
SO
57
STRS Ohio
Ohio
$391K +$29.3K +800 +9%
Asset Management One
58
Asset Management One
Japan
$374K
ARTA
59
A.R.T. Advisors
New York
$350K +$65.9K +1,800 +26%
DCM
60
Dupont Capital Management
Delaware
$349K +$320K +8,749 New
CAM
61
ClariVest Asset Management
California
$332K +$14.6K +400 +5%
TA
62
Teachers Advisors
New York
$315K +$32.1K +877 +13%
ADEF
63
Adams Diversified Equity Fund
Maryland
$272K +$249K +6,800 New
UBS Group
64
UBS Group
Switzerland
$222K +$8.02K +219 +4%
AIM
65
Acrospire Investment Management
Illinois
$208K -$126K -3,427 -40%
RhumbLine Advisers
66
RhumbLine Advisers
Massachusetts
$205K +$188K +5,130 New
MLICM
67
Metropolitan Life Insurance Company (MetLife)
New York
$180K +$26.3K +718 +19%
Deutsche Bank
68
Deutsche Bank
Germany
$170K -$364K -9,948 -70%
BG
69
BlackRock Group
United Kingdom
$170K
Manulife (Manufacturers Life Insurance)
70
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$164K +$28.3K +772 +23%
Bank of Montreal
71
Bank of Montreal
Ontario, Canada
$152K +$476 +13 +0.3%
CCMH
72
Cornerstone Capital Management Holdings
New York
$144K -$14.6K -400 -10%
NFA
73
Nationwide Fund Advisors
Ohio
$142K +$7.95K +217 +6%
AIG
74
American International Group
New York
$124K +$4.62K +126 +4%
US Bancorp
75
US Bancorp
Minnesota
$121K +$19.2K +525 +21%

BSTC Hedge Fund Activity: Q2 2016 in Review

90 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q2 2016, worth a combined $156M — up 17% from $134M a quarter earlier.

Fund positioning in BSTC was balanced in Q2 2016: 9 funds opened new positions, 9 closed out, 48 added to existing stakes and 16 trimmed.

The largest buyer was Eagle Asset Management, opening a new position worth an estimated $4.35M. The largest seller was Abdiel Capital Advisors, exiting entirely with an estimated $11.8M sold.

  • 90 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q2 2016, down from 91 in Q1 2016.
  • Funds reported $156M of BioSpecifics Technologies Corp. stock for Q2 2016, up 17% quarter-over-quarter.
  • 9 funds opened new BioSpecifics Technologies Corp. positions in Q2 2016 and 9 closed out, a net change of 0 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q2 2016 was Eagle Asset Management, an estimated $4.35M added.
  • The largest BioSpecifics Technologies Corp. seller in Q2 2016 was Abdiel Capital Advisors, an estimated $11.8M sold.

Based on aggregated 13F filings for Q2 2016.